Failed PhI­I­Is af­ter a re­jec­tion by the FDA spur Sanofi to dump its $1.7B deal with Lex­i­con on di­a­betes drug — shares crash

Sanofi’s near­ly 4-year-old quest to ride Lex­i­con’s SGLT1/2 di­a­betes drug so­tagliflozin to a last place fin­ish in the field end­ed with an abrupt ex­it Fri­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.